Clinical Trial Detail

NCT ID NCT03590054
Title A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Rahul Aggarwal
Indications

Advanced Solid Tumor

transitional cell carcinoma

head and neck squamous cell carcinoma

melanoma

lung non-small cell carcinoma

Therapies

Abexinostat + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.